Summary: In adults with obesity participating in a double-blind clinical pharmacology study, once-daily oral semaglutide (dose-escalated to 50 mg over…
Browsing: Obesity
Summary: In adults with obesity-related heart failure with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥45%, and BMI ≥30…
Summary: In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), including those enrolled in the STEP-HFpEF and STEP-HFpEF…
PICO Description Population Patients with obesity-related heart failure with preserved ejection fraction (HFpEF), enrolled in the STEP-HFpEF program, involving 1,145…
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.
In children aged 6 to <12 years with obesity, liraglutide (3.0 mg daily, combined with lifestyle interventions) significantly reduced BMI and body weight compared to placebo with lifestyle interventions, though it was associated with increased gastrointestinal side effects.
In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.
In patients with obesity and knee osteoarthritis, once-weekly semaglutide (2.4 mg) significantly reduced body weight and pain compared to placebo, though it was associated with gastrointestinal side effects.
In adults with obesity (BMI ≥30 kg/m²), daily subcutaneous semaglutide significantly promoted weight loss compared to liraglutide and placebo, with gastrointestinal symptoms as the main side effect.